Table 1.
Baseline demographics and disease characteristics for patients with NASH.
| Parameters | Placebo (n = 25) |
20 mg QW PGBF (n = 24) |
10 mg QD PGBF (n = 23) |
|---|---|---|---|
| Age, mean (SD), years | 47 (11) | 51 (12) | 52 (10) |
| Sex, n (%) | |||
| Male | 9 (36) | 7 (29) | 9 (39) |
| Female | 16 (64) | 17 (71) | 14 (61) |
| BMI, mean (SD), mg/kg2 | 36 (7) | 35 (6) | 34 (4) |
| NAFLD activity score, mean (SD) | 4 (1) | 4 (1) | 5 (1) |
| ALT, mean (SD), IU/L | 76 (53) | 72 (33) | 67 (46) |
| AST, mean (SD), IU/L | 49 (30) | 53 (23) | 50 (26) |
| HFF, mean (SD), % | 21 (8) | 20 (6) | 18 (8) |
| Triglycerides, mean (SD), mg/dl | 205 (134) | 192 (56) | 195 (89) |
| Total cholesterol, mean (SD), mg/dl | 197 (59) | 199 (49) | 196 (42) |
| HDL, mean (SD), mg/dl | 49 (10) | 45 (12) | 47 (11) |
| LDL, mean (SD), mg/dl | 122 (56) | 128 (44) | 122 (35) |
| HbA1c, mean (SD), % | 6.1 (1.1) | 6.3 (1.2) | 6.1 (1.0) |
| T2DM, n (%) | 11 (44) | 9 (38) | 9 (39) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HbA1c, glycated haemoglobin; HFF, hepatic fat fraction; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PGBF, pegbelfermin; QD, once daily; QW, once weekly; T2DM, type 2 diabetes mellitus.